Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PTGX

PTGX - Protagonist Therapeutics Inc Stock Price, Fair Value and News

$81.76-1.32 (-1.59%)
Market Closed

28/100

PTGX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

28/100

PTGX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$66.48

Target 3M

$74.79

Target 6M

$70.63

PTGX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PTGX Price Action

Last 7 days

-2.5%

Last 30 days

-7.0%

Last 90 days

5.0%

Trailing 12 Months

115.2%

PTGX RSI Chart

PTGX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PTGX Valuation

Market Cap

5.1B

Price/Earnings (Trailing)

111.34

Price/Sales (Trailing)

24.43

EV/EBITDA

101.8

Price/Free Cashflow

80.22

PTGX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$66.48

Target 3M

$74.79

Target 6M

$70.63

PTGX Fundamentals

PTGX Revenue

Revenue (TTM)

209.2M

Rev. Growth (Yr)

0.79%

Rev. Growth (Qtr)

-15.04%

PTGX Earnings

Earnings (TTM)

45.9M

Earnings Growth (Yr)

-18.46%

Earnings Growth (Qtr)

-13.14%

PTGX Profitability

EBT Margin

22.98%

Return on Equity

7.11%

Return on Assets

6.54%

Free Cashflow Yield

1.25%

PTGX Investor Care

Shares Dilution (1Y)

4.90%

Diluted EPS (TTM)

0.65

PTGX Alerts

  • 3 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025207.8M209.2M209.2M0
2024153.6M247.2M340.8M434.4M
202300060.0M
202246.9M45.5M35.2M26.6M
202131.2M27.2M24.4M27.4M
202020.0M22.8M25.7M28.6M
201921.7M014.2M17.1M
201831.3M42.5M39.9M30.9M
201700020.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Protagonist Therapeutics Inc

PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
 CEO
 WEBSITEprotagonist-inc.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES106

Protagonist Therapeutics Inc Frequently Asked Questions

PTGX is the stock ticker symbol of Protagonist Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Protagonist Therapeutics Inc is 5.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PTGX's fair value in chart for subscribers.

The fair value guage provides a quick view whether PTGX is over valued or under valued. Whether Protagonist Therapeutics Inc is cheap or expensive depends on the assumptions which impact Protagonist Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTGX.

As of Wed Jan 28 2026, PTGX's PE ratio (Price to Earnings) is 111.34 and Price to Sales (PS) ratio is 24.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTGX PE ratio will change depending on the future growth rate expectations of investors.